Veradermics (NYSE:MANE) Sees Unusually-High Trading Volume – Here’s Why

Shares of Veradermics, Incorporated (NYSE:MANE) saw strong trading volume on Thursday. 437,247 shares traded hands during mid-day trading, a decline of 29% from the previous session’s volume of 616,318 shares. The stock last traded at $131.4130 and had previously closed at $110.95.

Wall Street Analysts Forecast Growth

MANE has been the subject of several recent research reports. Wall Street Zen upgraded shares of Veradermics from a “sell” rating to a “hold” rating in a research report on Saturday, August 1st. Citigroup reaffirmed a “buy” rating on shares of Veradermics in a research note on Tuesday, September 15th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Veradermics in a report on Friday, August 21st. B. Riley Financial assumed coverage on Veradermics in a research note on Wednesday, July 15th. They issued a “buy” rating and a $170.00 target price on the stock. Finally, Lifesci Capital initiated coverage on Veradermics in a report on Tuesday, June 16th. They set an “outperform” rating and a $135.00 target price on the stock. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $153.00.

Veradermics Price Performance

The company’s 50 day simple moving average is $108.18 and its 200 day simple moving average is $100.45. The stock has a market cap of $5.46 billion and a P/E ratio of -68.83.

Veradermics (NYSE:MANE) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.58) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.58). On average, equities research analysts predict that Veradermics, Incorporated will post -2.74 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Timothy August Durso sold 43,500 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $107.82, for a total value of $4,690,170.00. Following the completion of the transaction, the insider directly owned 78,142 shares in the company, valued at approximately $8,425,270.44. The trade was a 35.76% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Reid Alexander Waldman sold 67,500 shares of the stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $107.86, for a total value of $7,280,550.00. Following the sale, the chief executive officer directly owned 170,824 shares of the company’s stock, valued at approximately $18,425,076.64. The trade was a 28.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 961,000 shares of company stock valued at $103,120,220.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in MANE. Arizona State Retirement System bought a new stake in shares of Veradermics during the second quarter worth $524,000. Private Capital Advisors Inc. increased its holdings in Veradermics by 158.4% during the 3rd quarter. Private Capital Advisors Inc. now owns 6,291 shares of the company’s stock worth $763,000 after purchasing an additional 3,856 shares in the last quarter. Wellington Management Group LLP bought a new position in Veradermics during the 2nd quarter worth about $8,425,000. Seven Fleet Capital Management LP acquired a new stake in shares of Veradermics in the 2nd quarter valued at about $9,835,000. Finally, Bamco Inc. NY lifted its holdings in shares of Veradermics by 284.8% in the second quarter. Bamco Inc. NY now owns 229,581 shares of the company’s stock valued at $28,225,000 after purchasing an additional 169,913 shares in the last quarter.

About Veradermics

Veradermics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for dermatologic diseases. The company’s research and development efforts are aimed at addressing conditions that affect the skin, hair and nails, with an emphasis on treatments designed to improve patient outcomes and quality of life.

Veradermics is advancing a pipeline of investigational dermatology products across multiple disease areas. Its activities include the discovery, clinical development and potential commercialization of prescription therapies for conditions with unmet medical needs.